Dr. Daniel Y. Wang
Claim this profileBaylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Studies Skin Cancer
Studies Lung Cancer
6 reported clinical trials
17 drugs studied
Area of expertise
1Skin Cancer
Stage IV
Stage III
BRAF positive
2Lung Cancer
Stage IV
HER2 positive
EGFR negative
Affiliated Hospitals
Clinical Trials Daniel Y. Wang is currently running
Oncolytic Virus + CAR T-Cell Therapy
for Solid Cancers
This study is a first in human Phase 1 study that involves patients with a type of cancer called HER2 (Human Epidermal Growth Factor Receptor 2) positive cancer. This study asks patients to volunteer to take part in a research study investigating the safety and efficacy of using special immune cells called HER2 chimeric antigen receptor specific cytotoxic T lymphocytes (HER2 specific CAR T cells), in combination with intra-tumor injection of CAdVEC, an oncolytic adenovirus that is designed to help the immune system including HER2 specific CAR T cell react to the tumor. The study is looking at combining these two treatments together, because we think that the combination of treatments will work better than each treatment alone. We also hope to learn the best dose level of the treatments and whether or not it is safe to use them together. In this study, CAdVEC will be injected into participants tumor at one tumor site which is most easiest to reach. Once it infects the cancer cells, activation of the immune response will occur so it can attack and kill cancer cells. (This approach may have limited effects on the other tumor sites that have not received the oncolytic virus injection, so, patients will also receive specific T cells following the intratumor CAdVEC injection.) These T cells are special infection-fighting blood cells that can kill cells infected with viruses and tumor cells. Investigators want to see if these cells can survive in the blood and affect the tumor. Both CAdVEC and HER2-specific autologous CAR T are investigational products. They are not approved by the FDA.
Recruiting1 award Phase 115 criteria
VO + Nivolumab
for Advanced Melanoma
This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease progressed on an anti PD-1 and an anti-CTLA-4 containing regimen (administered either as a combination regimen or in sequence) or who are not candidates for treatment with an anti-CTLA-4 therapy.
Recruiting2 awards Phase 33 criteria
More about Daniel Y. Wang
Clinical Trial Related3 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Daniel Y. Wang has experience with
- Pembrolizumab
- Therapeutic Conventional Surgery
- Avelumab
- Biopsy
- Biospecimen Collection
- Computed Tomography
Breakdown of trials Daniel Y. Wang has run
Lung Cancer
Breast Cancer
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Daniel Y. Wang specialize in?
Daniel Y. Wang focuses on Skin Cancer and Lung Cancer. In particular, much of their work with Skin Cancer has involved Stage IV patients, or patients who are Stage III.
Is Daniel Y. Wang currently recruiting for clinical trials?
Yes, Daniel Y. Wang is currently recruiting for 2 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Daniel Y. Wang has studied deeply?
Yes, Daniel Y. Wang has studied treatments such as Pembrolizumab, Therapeutic Conventional Surgery, Avelumab.
What is the best way to schedule an appointment with Daniel Y. Wang?
Apply for one of the trials that Daniel Y. Wang is conducting.
What is the office address of Daniel Y. Wang?
The office of Daniel Y. Wang is located at: Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.